S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
Log in
NASDAQ:TECH

Bio-Techne Stock Forecast, Price & News

$355.68
-0.99 (-0.28 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$350.65
Now: $355.68
$358.41
50-Day Range
$298.95
MA: $321.40
$356.67
52-Week Range
$155.17
Now: $355.68
$361.47
Volume145,839 shs
Average Volume173,779 shs
Market Capitalization$13.73 billion
P/E Ratio56.91
Dividend Yield0.36%
Beta1.13
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates in two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne logo

MarketRank

Overall MarketRank

1.75 out of 5 stars

Medical Sector

170th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

18th out of 177 stocks

Analyst Opinion: 1.2Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854
Employees2,300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.69 million
Cash Flow$6.61 per share
Book Value$36.13 per share

Profitability

Net Income$229.30 million

Miscellaneous

Market Cap$13.73 billion
Next Earnings Date2/2/2021 (Confirmed)
OptionableOptionable
$355.68
-0.99 (-0.28 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Bio-Techne (NASDAQ:TECH) Frequently Asked Questions

How has Bio-Techne's stock price been impacted by Coronavirus?

Bio-Techne's stock was trading at $180.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TECH shares have increased by 97.0% and is now trading at $355.68.
View which stocks have been most impacted by COVID-19
.

Is Bio-Techne a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Bio-Techne stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TECH, but not buy additional shares or sell existing shares.
View analyst ratings for Bio-Techne
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Bio-Techne?

Wall Street analysts have given Bio-Techne a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Techne wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Bio-Techne's CEO?

1,448 employees have rated Bio-Techne CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Bio-Techne's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Bio-Techne's next earnings date?

Bio-Techne is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Bio-Techne
.

How can I listen to Bio-Techne's earnings call?

Bio-Techne will be holding an earnings conference call on Tuesday, February 2nd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Bio-Techne's earnings last quarter?

Bio-Techne Co. (NASDAQ:TECH) issued its earnings results on Thursday, November, 5th. The biotechnology company reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.33. The biotechnology company had revenue of $204.20 million for the quarter, compared to the consensus estimate of $185.04 million. Bio-Techne had a return on equity of 12.20% and a net margin of 32.69%. The firm's revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.06 earnings per share.
View Bio-Techne's earnings history
.

How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?

Bio-Techne declared a quarterly dividend on Friday, November 6th. Shareholders of record on Monday, November 16th will be given a dividend of $0.32 per share on Friday, November 27th. This represents a $1.28 annualized dividend and a dividend yield of 0.36%. The ex-dividend date is Friday, November 13th.
View Bio-Techne's dividend history
.

Is Bio-Techne a good dividend stock?

Bio-Techne pays an annual dividend of $1.28 per share and currently has a dividend yield of 0.36%. The dividend payout ratio of Bio-Techne is 33.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 21.88% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.
View Bio-Techne's dividend history.

What price target have analysts set for TECH?

11 analysts have issued 1 year price targets for Bio-Techne's shares. Their forecasts range from $220.00 to $365.00. On average, they expect Bio-Techne's share price to reach $297.60 in the next year. This suggests that the stock has a possible downside of 16.3%.
View analysts' price targets for Bio-Techne
or view Wall Street analyst' top-rated stocks.

Who are some of Bio-Techne's key competitors?

What other stocks do shareholders of Bio-Techne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and The Boeing (BA).

Who are Bio-Techne's key executives?

Bio-Techne's management team includes the following people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 60, Pay $2.86M)
  • Mr. James T. Hippel, Exec. VP of Fin. & CFO (Age 49, Pay $1.15M)
  • Ms. Brenda S. Furlow, Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer (Age 62, Pay $821.24k)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 59, Pay $1.08M)
  • Mr. Kim Kelderman, Pres of Diagnostics & Genomics (Age 53, Pay $972.4k)
  • David Clair, Sr. Director of Investor Relations & Corp. Devel.
  • Mr. Gerry Andros, VP of Sales and Marketing
  • Mr. Struan Robertson, VP of HR
  • Mr. Robert M. Gavin, Sr. VP of Analytical Solutions Division (Age 52)
  • Mr. Kevin S. Gould, Sr. VP of Diagnostics Reagents Division (Age 54)

What is Bio-Techne's stock symbol?

Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."

Who are Bio-Techne's major shareholders?

Bio-Techne's stock is owned by a number of retail and institutional investors. Top institutional investors include Summit Creek Advisors LLC (0.17%), State of Alaska Department of Revenue (0.06%), Kestra Advisory Services LLC (0.03%), Louisiana State Employees Retirement System (0.03%), Tributary Capital Management LLC (0.02%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Bio-Techne stock include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, John L Higgins, Norman David Eansor, Robert V Baumgartner and Roeland Nusse.
View institutional ownership trends for Bio-Techne
.

Which major investors are selling Bio-Techne stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., Tributary Capital Management LLC, Diversified Trust Co, State of Alaska Department of Revenue, and Contravisory Investment Management Inc.. Company insiders that have sold Bio-Techne company stock in the last year include Alpna Seth, Brenda S Furlow, Charles R Kummeth, Harold J Wiens, James Hippel, Norman David Eansor, and Robert V Baumgartner.
View insider buying and selling activity for Bio-Techne
or view top insider-selling stocks.

Which major investors are buying Bio-Techne stock?

TECH stock was acquired by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, Peregrine Capital Management LLC, Summit Creek Advisors LLC, Gateway Investment Advisers LLC, Raymond James Trust N.A., Park Avenue Securities LLC, Exchange Traded Concepts LLC, and Louisiana State Employees Retirement System. Company insiders that have bought Bio-Techne stock in the last two years include Charles R Kummeth, and Robert V Baumgartner.
View insider buying and selling activity for Bio-Techne
or or view top insider-buying stocks.

How do I buy shares of Bio-Techne?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bio-Techne's stock price today?

One share of TECH stock can currently be purchased for approximately $355.68.

How big of a company is Bio-Techne?

Bio-Techne has a market capitalization of $13.73 billion and generates $738.69 million in revenue each year. The biotechnology company earns $229.30 million in net income (profit) each year or $3.86 on an earnings per share basis. Bio-Techne employs 2,300 workers across the globe.

What is Bio-Techne's official website?

The official website for Bio-Techne is www.bio-techne.com.

How can I contact Bio-Techne?

Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.